



**PRODUCT: Inmazeb™
(atoltivimab, maftivimab, and odesivimab-ebgn)**

COMPANY: Regeneron Pharmaceuticals

THERAPEUTIC AREA & INDICATION:
Treatment of infection caused by Zaire ebolavirus
in adult and pediatric patients

ABOUT THE PRODUCT

Long before COVID-19, Regeneron's infectious disease team tackled another one of the world's deadliest viruses: Ebola. Disproportionately impacting low-income countries and devastating communities, survival rates from Ebola outbreaks have been low as 10 percent.

Deploying Regeneron's proprietary VelociSuite® technologies and utilizing a strategic multi-antibody design to combat mutations, scientists created Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), the first FDA-approved treatment for Ebola, in record time. A breakthrough that will hopefully stem future outbreaks and help save lives, Inmazeb has defined Regeneron's approach to infectious disease and helped accelerate future drug development timelines.